MAR 10, 2017 6:20 PM PST

Towards Effective Immunotherapy for Prostate Cancer

WRITTEN BY: Carmen Leitch

Prostate cancer is the most common type to afflict men; around 160,000 new cases are diagnosed in the United States every year. Roughly one in forty men will eventually die from the disease but it can also be treated successfully. New work by researchers at The University of Texas MD Anderson Cancer Center has identified a potential treatment for advanced prostate cancer that is resistant to castration therapy, which could be a major step forward in a disease that is hard to treat in advanced stages. A combination of immune checkpoint blockers along with therapeutics targeting cells of the immune system that are associated with bad outcomes and lack of response to treatment. Learn more about metastatic, castration-resistant prostate cancer in the following video.

A mouse model was created and utilized to test out this treatment, one which uses immune system blockades and takes aim at myeloid  myeloid-derived suppressor cells (MDSCs). MDSCs are a type of immune cell that are derived from bone marrow stem cells, which have powerful abilities to suppress the immune system and are also understood to have an influence in cancer metastasis and the formation of tumors. The work has been reported in the journal Nature.

"A significant number of advanced prostate cancer patients treated with a chemical castration therapy called androgen deprivation therapy (ADT) experience relapse with relentless progression to lethal metastatic, castration-resistant prostate cancer," explained Ronald DePinho, M.D., a Professor of Cancer Biology. "While immune checkpoint blockade therapy is effective in many cancers, it has been less successful for this particular form of prostate cancer, which has motivated a search for targeted therapies that overcome this resistance."

For this study, the investigators tried the immune checkpoint blockades anti-CTLA4 and anti-PD1 together, and obtained "modest efficacy," commented the first author of the report,  Xin Lu, Ph.D., who trained with DePinho and now works as an independent investigator at the University of Notre Dame. Another concept they tested utilized MDSC-inhibiting drugs like cabozantinib (Cabo) and BEZ, but again found insignificant anti-tumor effects. Then these treatments were tried in unison, however, a successful result was achieved.

"Strikingly, both primary and metastatic castration-resistant prostate cancer responded to a combined checkpoint blockade and MDSC targeted therapeutic approach," said DePinho. "These observations in mouse models of prostate cancer, using a sophisticated genetic approach developed by James Horner at MD Anderson, illuminate a clinical path hypothesis for combining immune checkpoint blockades with MDSC-targeted therapies in the treatment of this aggressive cancer."

DePinho noted that future work including clinical trials are required to confirm the findings as well as to investigate the effects of this combination therapy and selective anti-androgen drugs for cases of established prostate cancer that is  castration-resistant, in addition to new diagnosed cases to obtain "durable clinical response."

 

Soucres: American Cancer Society, AAAS/Eurekalert! via MD Anderson, Nature

About the Author
BS
Experienced research scientist and technical expert with authorships on over 30 peer-reviewed publications, traveler to over 70 countries, published photographer and internationally-exhibited painter, volunteer trained in disaster-response, CPR and DV counseling.
You May Also Like
AUG 08, 2022
Cancer
A Protein Detectable in Blood Linked to Diabetes Onset and Cancer Mortality
AUG 08, 2022
A Protein Detectable in Blood Linked to Diabetes Onset and Cancer Mortality
Type 2 diabetes (T2D) is a well-established risk factor associated with some types of cancer, including liver, pancreas, ...
AUG 21, 2022
Cancer
The Legacy of Lady Mary Wortley Montagu
AUG 21, 2022
The Legacy of Lady Mary Wortley Montagu
Today, August 21, marks the 260th anniversary of the passing of a pioneer in the medical field.  In 1762, Lady Mary ...
AUG 25, 2022
Cancer
Nearly Half of Global Cancer Deaths Attributed to Behavioral Risk Factors
AUG 25, 2022
Nearly Half of Global Cancer Deaths Attributed to Behavioral Risk Factors
Cancer is a broad description of various related diseases resulting from abnormal and excessive cell growth.  While ...
SEP 15, 2022
Cancer
Early-Onset Cancers are Rising: Do We Know Why?
SEP 15, 2022
Early-Onset Cancers are Rising: Do We Know Why?
Early-onset cancers, typically defined as those diagnosed in people aged approximately 20 - 50, have continually increas ...
SEP 21, 2022
Cancer
Technology for Monitoring Tumors in Pre-Clinical Studies
SEP 21, 2022
Technology for Monitoring Tumors in Pre-Clinical Studies
Pre-clinical modeling, often using laboratory mice, is essential in developing life-saving therapies to treat cancer and ...
NOV 10, 2022
Plants & Animals
Treating Cancer in Dogs Using "Click" Chemistry
NOV 10, 2022
Treating Cancer in Dogs Using "Click" Chemistry
Researchers from California and Denmark were recently awarded the Nobel Prize in chemistry for the development of what&r ...
Loading Comments...